Health Canada has recently approved lecanemab (Leqembi), marking the first new Alzheimer’s treatment approved in over a decade and the first to target the underlying biology of the disease. This drug is intended for adults diagnosed with mild dementia due to Alzheimer’s and works by clearing amyloid plaques in the brain. However, access is limited to those without the APOE4 gene, which increases the risk of side effects. While the drug shows promise in slowing the disease’s progression, challenges include the need for intravenous administration, regular MRIs, and high costs, as well as the fact that the drug is not yet covered by public drug plans.
Read More
The Shopping Trends team has compiled information on consumer shopping patterns, potentially highlighting popular products or sales events. This team operates independently of CTV News journalists, indicating a separation between editorial content and commercial partnerships. Readers should be aware that the team may earn a commission through affiliate links used in their content. Further details about this arrangement are available on the Shopping Trends team’s “About Us” page.
Read More
Shopping Trends provides independent coverage and may receive commissions from purchases made through its links. This separation ensures the journalistic integrity of CTV News is maintained. The team aims to offer unbiased product recommendations and information. Readers are encouraged to consult the “Read about us” section for more details regarding the team’s practices and potential conflicts of interest.
Read More
The revelations about the Canadian DNA lab knowingly providing incorrect paternity test results are not just shocking but downright outrageous. The fact that this lab, Viaguard, continued to sell these tests despite being aware of the inaccuracies is beyond unethical, it’s downright criminal. The impact that these false results would have on families and individuals is immeasurable, causing emotional turmoil, relationship breakdowns, financial strain, and irreparable damage.
Reading about the methods used by the lab, such as entering menstrual cycle information into an ovulation calendar to determine paternity, is not only absurd but also dangerous. The idea that Dr. Tenenbaum, the director of the lab, would confidently assert the paternity of individuals without concrete evidence is appalling.… Continue reading
John Q. Hosedrinker